References
- Alsaidan AA, Al-Kuraishy HM, Al-Gareeb AI, et al. The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. Immun Inflamm Dis 2023;11:e798.
- Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021;76:970-9.
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461-7.
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237-69.
- Glance LG, Joynt Maddox KE, Shang J, et al. The COVID-19 pandemic and associated inequities in acute myocardial infarction treatment and outcomes. JAMA Netw Open 2023;6:e2330327.
- Thyagaturu H, Roma N, Angirekula A, et al. Trends and outcomes of type 2 myocardial infarction during the COVID-19 pandemic in the United States. Korean Circ J 2023;53:829-39.
- Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021;121:422-32.
- Chaudhary R, Bliden KP, Kreutz RP, et al. Race-related disparities in COVID-19 thrombotic outcomes: beyond social and economic explanations. EClinicalMedicine 2020;29:100647.
- Hayashi H, Izumiya Y, Fukuda D, et al. Real-world management of pharmacological thromboprophylactic strategies for COVID-19 patients in Japan: from the CLOT-COVID study. JACC Asia 2022;2:897-907.
- Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J 2021;51:202-21.